![]() Agios Pharmaceuticals Agios Pharmaceuticals is a biopharmaceutical company discovering and developing therapeutics for cancer metabolism. | Forbius Forbius (also known as Formation Biologics) is a protein engineering company that develops biotherapeutics for the treatment of cancer and fibrotic diseases. | Courier Therapeutics Courier Therapeutics is a biotechnology company providing a cytotoxic-lymphocyte targeting therapy platform. | ![]() Olema Oncology Olema Oncology (also known as Olema Pharmaceuticals) is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers. | ![]() Repare Therapeutics Repare Therapeutics is a company that develops oncology drugs for patients that target specific vulnerabilities of tumor cells. | ||
Founding Date | Founding Date 2008 | Founding Date 2011 | Founding Date 2015 | Founding Date 2007 | Founding Date 2016 | Founding Date 2017 |
Type | Type Public | Type Subsidiary | Type Private | Type Public | Type Public | Type Public |
Tags | ||||||
Locations | Locations Cambridge, US HQ | Locations Austin, US HQ Montréal, CA | Locations Houston, US HQ Houston, US | Locations San Francisco, US HQ San Francisco, US | Locations Montréal, CA HQ Cambridge, US | Locations Salt Lake City, US HQ Wuxi, CN Walluf, DE Willich, DE Milano, IT Doetinchem, NL Calamba, PH see more |
Employees | Employees 53611% increase | Employees 811% decrease | Employees 1 | Employees 9630% increase | Employees 129 | Employees 2,4004% increase |
Valuation ($) | Valuation ($) 2.7 b | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 679.2 m | Valuation ($) 152.4 m | Valuation ($) 543.9 m |
Financial | ||||||
Revenue (est.) | Revenue (est.) $54m (FY, 2025) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) $53.5m (FY, 2024) | Revenue (est.) $844.6m (FY, 2025) |
Cost of goods | Cost of goods $6.3m (FY, 2025) | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A | Cost of goods $554.1m (FY, 2025) |
Gross profit | Gross profit $47.7m (FY, 2025) | Gross profit N/A | Gross profit N/A | Gross profit N/A | Gross profit $53.5m (FY, 2024) | Gross profit $290.5m (FY, 2025) |
Net income | Net income ($412.8m) (FY, 2025) | Net income N/A | Net income N/A | Net income ($162.5m) (FY, 2025) | Net income ($84.7m) (FY, 2024) | Net income ($69.9m) (FY, 2025) |
Funding | ||||||
Total funding raised | Total funding raised N/A | Total funding raised N/A | Total funding raised N/A | Total funding raised $ 145.1m | Total funding raised $ 150.5m | Total funding raised N/A |
Forbius (also known as Formation Biologics) is a protein engineering company that develops biotherapeutics for the treatment of cancer and fibrotic diseases.
View companyCourier Therapeutics is a biotechnology company providing a cytotoxic-lymphocyte targeting therapy platform.
View company
Olema Oncology (also known as Olema Pharmaceuticals) is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers.
View company
Repare Therapeutics is a company that develops oncology drugs for patients that target specific vulnerabilities of tumor cells.
View company